![]() This software is designed to be used as a decision support tool and to be used with a patient’s clinical history, continuous monitoring data, diagnostic test results and clinical judgement.Ĭlew Medical said the system is not able to predict sudden deterioration, but rather analyzes trends in data that occur over time. The system is cleared for use in adults in ICU while treating COVID-19 as a diagnostic aid with the early identification of patients who are likely to experience respiratory failure or hemodynamic instability. It uses commonly recorded vital signs, nursing assessments, flowsheet data, medications and lab data to compute patient status indexes.ĭata defined by the system includes CLEWRF, which is a measure of a patient’s predicted physiologic condition within the next eight hours based on the aggregate statistical risk of respiratory deterioration or failure, and CLEWHI, which is a measure of a patient’s predicted physiological condition within the next eight hours based on the aggregate statistical risk of hemodynamic instability. in Bio Medical Engineering, from Tel Aviv University in. ![]() Prior to joining CLEW in 2017, Noa served as a Product Manager at Change Healthcare (fka McKesson). The system is a standalone software that is designated as a medical device. Noa Berger-Kurtzer is a seasoned Product Executive with over 10 years of experience in introducing innovative clinical products into the global healthcare ecosystem. The EUA covers the company’s ClewICUServer and ClewICUnitor. We are committed to improving the health of people in Central Massachusetts through excellence in care, comprehensive health services, teaching and research.Clew Medical recently received FDA emergency use authorization for its ClewICU System for use in intensive care units. UMass Memorial Medical Center is the region's trusted academic medical center, part of the UMass Memorial Health Care system. ![]() Originally developed and proven in the ICU, these models optimize scarce clinical resources and guide health care providers in predicting patient deterioration, across all care settings.ĬLEW Medical is headquartered in Netanya, Israel, and led by CEO Gal Salomon. The platform uses machine learning and data science technology to develop physiological, predictive models at the level of each individual patient in order to deliver predictive warnings during all phases of a patient's stay. "In our partnership with CLEW, I am excited to see just what these advanced tools can do within UMASS Medical Center."ĬLEW Medical (formerly Intensix), is a real time AI analytics platform designed to predict life threatening complications across various medical care settings, and help providers make better informed clinical decisions, improve outcomes and safety, streamline patient care, efficiently handle regulations and penalties, and lower the cost of care. "Electronic tools that enhance situational awareness are a key component of telemedicine support for patients and their healthcare communities," said Craig Lilly, Vice Chair of Critical Care at UMASS. "Teaming up with such a prestigious hospital is a great privilege, and we're thrilled to have CLEW's platform integrated into UMass Medical's Tele-ICU program, which will help with time sensitive decisions and creating a new standard for patient care," says Gal Salomon, CEO and Founder of CLEW. ![]() These predictions will be based on clinical data leveraged from UMass Medical Center's Tele-ICUs, monitoring five different facilities, and approximately 150 patients in real-time. Through this partnership, CLEW will expand its advanced clinical trials for its real-time, patient-level predictions based on AI algorithms, and customized physiological models, at UMass Memorial. 17, 2021 /PRNewswire/ - CLEW Medical has. Murphy have joined the company's Advisory Board. CLEW's AI platform will provide UMass Medical with the tools to enhance its patient care, and reduce costs by preventing clinical deteriorations, while maximizing healthcare resources. CLEW Medical will benefit from their extensive experience and background in the healthcare industry as a vital part of the company's plans for North American expansion and commercialization.ollowing recent FDA approval of the CLEWICU solution, Dr. The company's innovative prediction models and advanced analytics engine detects deterioration in real-time, and delivers predictive warnings during all phases of a patient's Tele-ICU stay. 29, 2018 /PRNewswire/ - CLEW, developers of an innovative, personalized clinical analytics platform optimizing the level of a patient's care, announced today its partnership with UMass Memorial Medical Center, one of the largest academic medical centers in Massachusetts.ĬLEW's platform analyzes the hundreds of thousands of data points the average critical care patient in a US hospital provides every minute, to help clinicians make timely decisions with actionable clinical, operational and financial insights. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |